A New Important Milestone: The AIDA Still’s Disease Registry Surpasses 800 Patients

The AIDA Network is proud to announce a new and significant milestone in the field of autoinflammatory diseases: the AIDA Still’s Disease Registry has surpassed 800 enrolled patients. This important achievement confirms the strength of global cooperation in generating high-quality real-world data, which are essential for improving the understanding and management of this complex condition.

Since its launch, the registry has established itself as a valuable resource for international clinical research. Numerous scientific publications have already emerged from the collected data, making meaningful contributions to the understanding of Still’s disease pathogenesis, clinical features, and therapeutic strategies. Many other research projects are currently ongoing, further demonstrating the dynamism and growing impact of this initiative.

The continuous expansion of the registry has been made possible by the active participation of 345 centers across 53 countries within the AIDA Network, involving 1,113 investigators engaged in the registry’s activities. Each new participating center enhances the diversity and representativeness of the data, offering an increasingly global and inclusive view of the disease.

This robust real-life dataset allows for the exploration of unanswered clinical questions and the development of increasingly targeted therapeutic approaches. The integration of clinical experiences from diverse geographical contexts makes it possible to overcome the limitations of single-center studies, providing a broader and more practical understanding of Still’s disease.

With more than 800 enrolled patients, the AIDA Still’s Disease Registry now stands as the largest active international registry dedicated to this condition. This milestone lays a solid foundation for future breakthroughs and tangible improvements in patient care.

Our heartfelt thanks go to all researchers, investigators, and centers who have contributed—and continue to contribute—to the success of this ambitious project. Together, we are building a more informed, collaborative, and patient-centered future for Still’s disease.